Using increasing concentrations of the Bcl-2 homology domain 3 (BH3) peptide of the BH3-only protein Bim (0.1–3.0 μM) showed that chemo- and targeted therapy-resistant melanoma cells did not grossly differ in their basal priming status (Fig. 5a and Supplementary Fig. 5a–c). Here, BCL2L11 is linked to melanoma.